CRP and cardiovascular disorder: In our study, the 56% decrease in CRP is clinically relevant because the value changed from a level considered “high risk” for cardiovascular disease at baseline (above 3.0 mg/L) to an “average risk” (1.0 to 3.0 mgL) after 1 year of the SARC intervention.